Literature DB >> 24951308

Low flucloxacillin concentrations in a patient with central nervous system infection: the need for plasma and cerebrospinal fluid drug monitoring in the ICU.

Mohd H Abdul-Aziz1, Craig McDonald2, Brett McWhinney3, Jacobus P J Ungerer3, Jeffrey Lipman4, Jason A Roberts4.   

Abstract

OBJECTIVE: To report the difficulty in achieving and maintaining target antibiotic exposure in critically ill patients with deep-seeded infections. CASE
SUMMARY: We present a case of a 36-year-old man who was admitted to the intensive care unit with diffuse central nervous system and peripheral methicillin-sensitive Staphylococcus aureus infection (minimum inhibitory concentration; MIC, 1 µg/mL). Owing to the complicated nature of the infection, sequential concentrations of free flucloxacillin were measured in plasma and cerebrospinal fluid (CSF) and used to direct antibiotic dosing. Unsurprisingly, the trough plasma concentrations of flucloxacillin were below the MIC (0.2-0.4 µg/mL), and the corresponding CSF concentrations were undetectable (<0.1 µg/mL) with standard intermittent bolus dosing of 2 g every 4 hours. By administering flucloxacillin by continuous infusion (CI) and increasing the dose to 20 g daily, the plasma (2.2-5.7 µg/mL) and CSF (0.1 µg/mL) levels were increased, albeit lower than the predefined targets (plasma, 40 µg/mL; CSF, 4 µg/mL). DISCUSSION: The presence of physiological changes associated with critical illness-namely, hypoalbuminemia and augmented renal clearance-may significantly alter antibiotic pharmacokinetics, and this phenomenon may lead to suboptimal antibiotic exposure if they are not accounted for. This case also highlights the value of applying CI in such patient groups and demonstrates the significance of monitoring plasma and CSF drug concentrations in optimizing antibiotic delivery.
CONCLUSIONS: Future research should aim to evaluate the utility of such drug monitoring with regard to patient outcomes and cost-effectiveness.
© The Author(s) 2014.

Entities:  

Keywords:  cerebrospinal fluid; intensive care unit; pharmacokinetics; therapeutic drug monitoring; β-lactams

Mesh:

Substances:

Year:  2014        PMID: 24951308     DOI: 10.1177/1060028014540610

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  6 in total

1.  Effective CSF concentrations achieved with continuous-infusion flucloxacillin in a child.

Authors:  Alison Boast; Jeremy Carr; Nigel Curtis; Andrew J Daley; Amanda Gwee
Journal:  Eur J Clin Pharmacol       Date:  2015-08-26       Impact factor: 2.953

Review 2.  [Adequate anti-infective treatment : Importance of individual dosing and application].

Authors:  A Brinkmann; A C Röhr; A Köberer; T Fuchs; W A Krüger; C König; D Richter; M A Weigand; O R Frey
Journal:  Anaesthesist       Date:  2018-06       Impact factor: 1.041

3.  A systematic review of the effect of therapeutic drug monitoring on patient health outcomes during treatment with penicillins.

Authors:  Timothy Luxton; Natalie King; Christoph Wälti; Lars Jeuken; Jonathan Sandoe
Journal:  J Antimicrob Chemother       Date:  2022-05-29       Impact factor: 5.758

Review 4.  Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing.

Authors:  Sherif Hanafy Mahmoud; Chen Shen
Journal:  Pharmaceutics       Date:  2017-09-16       Impact factor: 6.321

5.  Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing.

Authors:  Eveline E Roelofsen; Brenda C M de Winter; Heleen van der Spek; Susan Snijders; Birgit C P Koch; Sanne van den Berg; Anouk E Muller
Journal:  Antibiotics (Basel)       Date:  2022-08-03

Review 6.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.